DTP: profitable, cash-rich pharmacy play with limited near-term upside
Intrinsic value VND 68,359 vs market VND 64,000 — implied upside 6.8% (confidence: very_low).
Tổng quan doanh nghiệp
Công ty Cổ phần Dược phẩm CPC1 Hà Nội (DTP) is a UPCOM-listed pharmaceutical company operating in the domestic drug manufacturing and distribution segment (ICB: Dược phẩm). Revenue grew from VND 1,113.5 bn in 2023 to VND 1,694.9 bn in 2025, reflecting expanding sales reach and product mix. The firm reports healthy margins (gross margin 53.96%, EBIT margin 20.29%) and returns (ROE 26.1%, ROA 19.8%), supported by light financial leverage (Debt/Equity 0.32).
Luận điểm đầu tư
DTP combines double-digit top-line growth with strong profitability metrics: revenue CAGR has accelerated to large growth (2025 revenue VND 1,694.9 bn) and net profit rose to VND 283.4 bn in 2025. Valuation multiples are low versus many peers (P/E 7.5, EV/EBITDA 4.9), and the company shows material operating quality (earnings_quality 94.4/100).
However, the implied upside is limited — the blended DCF+PE intrinsic value of VND 68,359 per share gives only 6.8% upside to the current market price of VND 64,000 and the model confidence is explicitly very_low. Liquidity is a concern: average daily volume over 2 weeks is 1,474 shares and the stock trades on UPCOM with foreign_room 0.0, which constrains price discovery and institutional interest. Ownership is concentrated among a small group of individuals and the parent CPC1 entity (top five holders together >72%), which creates execution and governance concentration risk.
On balance, the company’s cash-generative core business and net profitability reduce downside risk, but the narrow margin of valuation safety, low model confidence and illiquidity make it hard to justify new material allocations at current prices.
Bình luận định giá
Blended intrinsic valuation: 70% DCF and 30% PE multiple, using a 10-year projection and terminal growth.
- Base FCF in model: VND 43,214,036,789 (model input 'base_fcf') used for DCF sizing
- Model WACC 10.0% with terminal growth 4.0% (wacc components: ke 11.1%, kd after tax 5.89%)
- Blend weights: 70% DCF (DCF intrinsic VND 30,372.3 per share) and 30% PE (PE intrinsic VND 92,046.6 per share)
- Fair PE used: 10.54x with a PE cap 25x and projection horizon 10 years
- Model flags: net-debt reported as negative (net cash) and sanity flag 'illiquid'; calibration method 'isotonic' and final intrinsic value VND 68,359 per share
The blended intrinsic value implies modest upside (6.8%) and the valuation depends heavily on DCF assumptions (70% weight). Given the model's very_low confidence and the UPCOM illiquidity flag, our conviction in the precise VND 68,359 target is low — the value is best treated as a directional check rather than a high-confidence price target.
Quan điểm tích cực và tiêu cực
- High profitability: ROE 26.1% and EBIT margin 20.3%, supporting sustainable cash generation.
- Rapid recent revenue growth: revenue rose to VND 1,694.9 bn in 2025 (2025 vs 2023 base), with net profit of VND 283.4 bn in 2025.
- Cheap multiples vs fundamentals: P/E 7.5 and EV/EBITDA 4.9 imply valuation buffer relative to many peers.
- Limited upside: blended intrinsic value implies only 6.8% upside to the current market price of VND 64,000 per share, and model confidence is very_low.
- Illiquidity and listed venue: avg volume 2w only 1,474 shares and trading on UPCOM reduces price discovery and makes exits costly.
- Ownership concentration: top five shareholders control a large block (top holder 19.3%, two others 17.2% and 16.4%), raising governance and related-party risk.
Bối cảnh ngành
The Vietnamese pharmaceuticals subsector is competitive and fragmented, with many listed small- to mid-caps. Regulatory factors matter: VAS accounting treatment differs from IFRS in provisions and related-party disclosures; state influence remains via legacy SOE stakes in some players (relevant here since one top holder is 'Công ty Cổ phần Dược phẩm Trung ương CPC1'). Monetary/regulatory context also matters for banks and working capital financing (SBV credit growth quotas can indirectly affect distributors and trade receivables funding). Peer comparison shows median sector upside of 12.1% (351 peers), placing DTP below the sector median on our model's output.
Yếu tố rủi ro
- Illiquidity risk: average 2-week volume 1,474 shares increases execution cost and widens realized volatility.
- Model confidence: valuation flagged as very_low; sensitive to WACC, growth and terminal assumptions (DCF weight 70%).
- Concentrated ownership: top five holders combine for over 72% of shares (largest 19.3%), which can limit minority shareholder influence and increase related-party transaction risk.
- Listing venue: UPCOM listings frequently suffer from thin trading and limited analyst coverage, reducing transparency.
- Foreign ownership: foreign_room 0.0 restricts demand from offshore funds, potentially capping rerating catalysts.
- Policy/regulatory: drug registration, price controls, and procurement rules can compress margins or delay product launches.
Yếu tố xúc tác
- Quarterly or annual results that beat consensus on revenue and net profit growth (recent revenue 2025: VND 1,694.9 bn; net profit 2025: VND 283.4 bn).
- Any improvement in liquidity or transfer to HSX/HOSE (would broaden investor base), or an increase in foreign_room.
- Corporate actions that improve minority liquidity or governance (share buyback, listing upgrade, or dividend policy change).
Đánh giá pháp y tài chính
No Beneish M-Score is available and no forensic red flags were flagged in the input. Earnings quality is high at 94.4/100, suggesting reported profits are broadly supported by cash and accounting items. Given concentrated ownership, standard governance vigilance is warranted despite the absence of explicit forensic flags.
Lịch sử dự báo
Model track record spans 7 years with a hit_rate of 0.5 (50%), and an average historical upside of 36.6% when calls were correct. The 50% hit rate is mediocre — useful for directional guidance but not highly reliable. Given the model's recalibrated very_low confidence for this valuation, reliance on historical model performance should be tempered.
Được viết bởi mô hình ngôn ngữ ngày 2026-08-10 dựa trên kết quả mô hình và báo cáo tài chính của chính trang này, và có thể trích dẫn số liệu tại thời điểm đó. Đây là phân tích mô tả, không phải khuyến nghị đầu tư — không đưa ra hay hàm ý bất kỳ khuyến nghị mua, bán hay nắm giữ nào.